Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide plus NB-UVB for Nonsegmental Vitiligo
NCT04525157Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Feb 2016
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 2 trial of Afamelanotide in nonsegmental vitiligo (NSV), sponsored by Clinuvel Pharmaceuticals. Started Jun 2014; status: completed.
02
Drugs
Afamelanotide
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT04525157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525157.